Appendix Table E107. Baseline characteristics of patients with ischemic heart disease in studies assessing the predictive ability of miscellaneous platelet function tests

| **Author, year [ref]**  **UID**  **Country**  **Study Name** | **Total N Enrolled**  **Race (% by group)**  **Male (%)**  **Age\*** | **Previous CAD (%)**  **Previous heart failure(%)**  **Previous TIA/stroke(%)**  **History of PCI or CABG(%):**  **Stable angina(%)**  **Unstable angina(%)**  **Previous PAD(%)**  **History of MI(%)**  **STEMI/non-STEMI(%)** | **Dyslipidemia (%)**  **Smokers (%)**  **BP(mmHg diastolic/systolic**  **HTN (%)**  **Diabetes (%)** | **Vitamin K antagonist(%)**  **Clopidogrel(%)**  **Aspirin(%)**  **PPI(%)** | **Stent implantation(%)**  **Type of stent(%)**  **Multi-or single vessel(%)** | **Current indication for clopidogrel treatment** | **Current antiplatelet regimen** | **Co-medication** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Smit, 2010  20889993  Netherlands  ON-TIME-2 | 648  NR  75.8  62.3 | NR  NR  CVA 1.7  PCI 7.4; CABG 2.5  15.2  NR  NR  7.8  STEMI 100 | 18.8  44.9  HTN 29.6; systolic 132.8 mmHg; diastolic 79.8 mmHg  9.9 | NR  NR  NR  NR | NR  NR  NR | Patients with ACS (STEMI) | Clopidogrel: (600 mg LD + 75 mg MD daily for 1 year); | acetylsalicylic acid 500 mg IV; unfractionated heparin 5000 IU IV ± tirobiban (25 mg/kg bolus + MD infusion of 0.15 mg/kg/min of tirofiban or placebo) |
| Dziewierze, 2005  15815794  Poland  NR | 31  NR  77.4  54.3±9.9 | NR  NR  NR  PCI 19.4; CABG 0;  100  NR  NR  61.3  NR | 74.2  25.8  58.1  12.9 | NR  NR  100 | NR  NR  multi 70.9 | Patients with stable angina selected for PCI | Loading dose 300 mg with 75 mg per day until PCI was performed or 28 days until stent had been implanted. | The use of GP IIb/IIIa inhibitors and heparin titration during PCI were left to the discretion of the operator. |
| Breet, 2010  20179285  Netherlands  POPULAR | 1069  NR  75  64±10.6 | NR  NR  NR  NR  NR  NR  NR  54.5  NR | 80.3  11.1  HTN 76.9  18.6 | NR  100  89.4  27.8 | 100  DES 63.5  NR | coronary artery disease scheduled for elective PCI with stent | clopidogrel treatment (a maintenance of 75 mg/d therapy for>5 days or a loading dose of 300 mg ≥24 hours before PCI or 600 mg ≥4 hours before PCI) and aspirin (80-100 mg/d ≥10 days). | unless they were receiving long-term anticoagulation with warfarins |
| Mobley, 2004  14969622  USA  NONE | 50  NR  NR  NR | NR  NR  NR  NR  NR  NR  NR  NR  NR | NR  NR  NR  NR | NR  NR  NR(most to be)  NR | NR  NR  NR | Candidates for cardiac catheterization with clinical suspicion of PCI who were on aspirin and clopidogrel | 75 mg clopidogrel per day after 300-mg loading dose (if physician judges the loading dose to be necessary); most patients already on aspirin | NR |
| Lindvall, 2009  19477870  Sweden  None | 15  NR  80  61.8±11.6 | NR  NR  NR  NR  NR  NR  NR  NR  NR | NR  NR  NR  NR | NR  NR  NR  NR | NR  NR  NR | Patients with ACS undergoing CABG | loading dose of 300 – 600 mg of clopidogel orally, followed by 75 mg daily; oral aspirin, 75 mg per day, | subcutaneous low molecular weight heparin. At the time of the study, aprotinin was routinely administered according to the Hammersmith regime: consisting of 2 million KIU before start of surgery, 2 million KIU in the CPB prime, and 500,00- KIU per hr during surgery . Aspirin and low molecular weight heparin treatment was continued until the day of surgery, but not given on the day of surgery. ACE inhibitors were omitted on the day of surgery. |
| Gurbel, 2003  12714161  USA  No | 63  NR  60  67±11 | NR  NR  NR  CABG 18  NR  NR  NR  24  NR | hyper 60  NR  HTN 72  39 | NR  100  100  NR | 100  NR  NR | Patients undergoing PCI with stenting | all received ± 81 mg of aspirin for 7 days before the procedure. All patients received the same clopidogrel regimen (300 mg in the catheterization laboratory after stent implantation, then 75 mg/day for 30 days) with 325 mg/day aspirin. | Heparin (activated clotting time >300 seconds) was administered to all patients immediately before stent implantation, and per protocol, GP IIb/IIIa inhibitors were not given. |
| Kim, 2010  20449634  Korea  NR | 1058  NR  70.1  62.2±11.2 | 62.2±11.2  NR  3.6%  PCI 30.4%  NR  NR  NR  20.9%  NR | 19%  39.8%  52%  29% | NR  25.3%  NR  NR | NR  NR  27.6% | Patients treated  with coronary stenting for symptomatic coronary artery disease, including acute myocardial infarction (AMI) and on chronic clopidogrel therapy | scheduled coronary stenting procedures, 300-mg loading-dose (LD)  of clopidogrel at least 12 h before procedure. In AMI patients, all received a 600-mg LD of clopidogrel immediately after emergency room arrival, followed by a maintenance dose of 75 mg daily. | If use of glycoprotein IIb/IIIa inhibitor (GPI) was deemed necessary, only tirofiban, which has a short half-life, was administered. |
| Kalantzi, 2012  21806493  Greece  NR | 40  NR  70  57.6±10.8 | NR  NR  NR  NR  NR  NR  NR  NR  NR | hyper 40  57.5  HTN 60  0 | NR  NR  NR  NR | NR  NR  NR  NR | patients with ACS with or without ST elevation | LD 325 mg aspirin+MD 100mg/day  heparin 1mg/kg every 12 h  LD 600mg clopidogrel+MD 75 mg/day | atorvastatin 40mg/day |
| Siller-Matula, 2012  22260716  PEGASUS-PCI | 416  NR  76  64±12 | NR  NR  NR  PCI 47  NR  NR  13  31  18/NR | hyper 76  55  84  32 | NR  100  100  76 | 100  DES 99  NR | patients undergoing PCI | clopidogrel LD 600mg, MD 75mg | NR |
| Saad, 2012  22146578  Egypt  NR | 90  NR  58%  56.2 y | 100%  NR  NR  NR  NR  NR  NR  NR  NR | Hypercholesterolemia: 31.1%  67%  19%  HTN: 57%  62% | NR  NR  100%  NR | NR  NR  NR | CAD patients for PCI | clopidogrel LD: 600 mg; MD: 75 mg/d; aspirin 162 mg/d | nitrates, b-blockers, lipid-lowering drugs, antihypertensive drugs and oral hypoglycemic drugs |
| Lakkis, 2001  11458412  USA  NR | 30  NR  NR  53 | NR  NR  NR  NR  NR  NR  NR  NR  NR | Hyper 66.7  NR  HTN 60  33.3 | NR  NR  NR  NR | 100  NR  NR | ACS patients with PCI | clopidogrel 300 mg and aspirin 325 mg | GP IIb/IIIa inhibitors |

\* Mean (standard deviation), unless otherwise stated.  
**Abbreviations:** NACS = acute coronary syndrome; AMI = acute myocardial infarction; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; PTCA=percutaneous transluminal coronary angioplasty; CVA=cerebrovascular accident; CVD=cerebrovascular disease; CAD = coronary artery disease; DES=Drug eluting stent; BMS=bare metal stent; HTN = hypertension, IHD: Ischemic heart disease; MI = myocardial infarction; NSTEMI = non-ST-elevation MI; LVEF=left ventricle ejection fraction; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; TIA = transient ischemic attack; PPI=proton pump inhibitor; UFH= Unfractionated Heparin; BP=blood pressure; hyper=hypercholesterolemia; LD=loading dose; MD= maintain dose; ASA=aspirin; GP IIb/IIIa inhibitors =Glycoprotein IIb/IIIa inhibitors.